Clinical trial Recruiting at 1 site Interventional Ages 21 to 50

Treating post-dural puncture headache with theophylline, sumatriptan, or gabapentin

Official title: A Comparison Between Safety and Efficacy of Theophylline, Versus Sumatriptan and Gabapentin in The Treatment of Post-Dural Puncture Headache: A Prospective Randomized Double Blinded Study

Run by Tanta University · NCT07515456 · Data updated 2026-11-12

This trial will try theophylline, sumatriptan, and gabapentin to see which best relieves moderate-to-severe post-dural puncture headache in adults aged 21–50.

Quick facts

Study typeInterventional
Ages21 Years to 50 Years
SexAll
Enrollment75 (estimated)
SponsorTanta University
Academic / other
Locations1 site (Tanta, El-Gharbia)
StatusRecruiting
StartedDecember 1, 2024
Main results expectedNovember 1, 2026
Study endsNovember 1, 2026
Registry record updatedApril 7, 2026
Trial IDNCT07515456 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 21–50 years old with PDPH meeting International Headache Society criteria, ASA physical status I–II, and a numeric pain rating of ≥5 are the intended participants.

Probably not a fit

People who are pregnant, have chronic headache disorders, significant cardiovascular disease, thyroid/liver/kidney impairment, or contraindications to the study drugs are unlikely to benefit from these treatments.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults aged 21–50 with clinically diagnosed post-dural puncture headache and a pain score of at least 5 are enrolled at Tanta University and given one of three medications (theophylline, sumatriptan, or gabapentin). The study compares how well each drug reduces headache severity and records side effects to compare safety. Treatments are given per protocol and patients are followed for clinical response and adverse events. Outcomes focus on pain relief magnitude and tolerability.

Why it matters

Potential benefit: If successful, the trial could identify an effective, low-cost medication option to relieve PDPH without needing invasive procedures.

How similar studies have gone: Smaller previous reports have suggested benefit from theophylline and sumatriptan for PDPH, but direct head-to-head comparative data are limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age from 21 to 50 years.
* Both sexes.
* American Society of Anesthesiologists (ASA) physical status ≤ II.
* Patient's selection for this study will be based on clinical diagnosis suggesting post-dural puncture headache (PDPH) based on the International Headache Society criteria.
* Patients with numeric rating scale (NRS) of ≥ 5.

Exclusion Criteria:

* Pregnant women.
* History of; chronic headache, cluster headache, migraine, convulsions, cerebrovascular accident, and previous neurological diseases.
* Signs of meningismus.
* Dysrhythmia.
* Hypertension.
* Ischemic heart disease.
* Hyperthyroidism.
* Peripheral vascular disease (ischemic colitis).
* Liver or renal impairment.
* Use of selective serotonin reuptake inhibitors.
* Use of ergotamine derivatives in the past 24 hours.
* Use of monoamine oxidase inhibitors in the last 2 weeks.
* Use of any kind of opiates.
* Allergy to the study medications and any contraindication of oral intake.

Where it's running

  • Tanta University
    Tanta, El-Gharbia, Egypt
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.